Sanofi (NASDAQ:SNY) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP raised its stake in Sanofi (NASDAQ:SNY) by 15.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,876 shares of the company’s stock after acquiring an additional 13,499 shares during the period. Quantinno Capital Management LP’s holdings in Sanofi were worth $5,698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new position in Sanofi in the third quarter valued at $29,000. POM Investment Strategies LLC acquired a new position in Sanofi in the second quarter valued at $25,000. Concord Wealth Partners boosted its stake in Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new position in Sanofi in the second quarter valued at $35,000. Finally, Fortitude Family Office LLC boosted its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after acquiring an additional 659 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY opened at $48.46 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a market capitalization of $122.98 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 1.22 and a beta of 0.58. The firm has a 50-day simple moving average of $52.08 and a 200-day simple moving average of $52.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.55 earnings per share. On average, equities research analysts anticipate that Sanofi will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.